Cell and Gene Manufacturing and Logistics

31. A Novel Non-Viral Platform For High-Efficiency T-Cell Engineering 9/22/2026

    Gain insight into how nuclease format, delivery method, and DNA template design influence knockout efficiency, targeted TCR integration, cell viability, and recovery.

32. Developing A Science- And Risk-Based Bio-Decontamination Control Strategy For Pharmaceutical Isolators 9/22/2026

    Modern contamination control links barrier design, bio-decontamination science, and risk-based validation to ensure reliable surface sterility.

33. Why Isn't One Assay Enough For Gene Editing Off-Target Safety Assessment? 9/22/2026

    Gene editing off-target risk cannot be captured by one assay. Combining biochemical, computational, and cell-based methods with deep sequencing provides a more complete view of potential edits.

34. Challenges And Opportunities For MSC Expansion Workflows 9/22/2026

    Discover how optimizing cell culture platforms and closed systems reduces manufacturing costs, improves media efficiency, and supports scalable stem cell production.

35. The Future Of Automation In CGT: Interview With Andreas Knaack 9/22/2026

    Scaling cell and gene therapies requires automation that protects critical biology while improving consistency. Learn why purpose-built technologies and industry collaboration will be essential.

36. Breaking The AAV Titer Barrier: A 9x Manufacturing Breakthrough 9/22/2026

    See how targeted optimization of cell culture media and transfection reagents increased AAV titers ninefold while improving full capsid percentages, strengthening HEK293 production, and more.

37. Structuring CGT Deals for the Long Term with Troutman Pepper Locke's EA Weeks, J.D., Ph.D. 9/22/2026

    In episode 138 of Cell & Gene: The Podcast, EA Weeks, J.D., Ph.D., Counsel at Troutman Pepper Locke talks to Host Erin Harris about the deal terms in CGT that matter most, including IP ownership, manufacturing capacity, CMC milestones, data rights, tech transfer, and more.

38. The Case For Synthetic DNA In Modern Therapeutic Development 9/22/2026

    Faster timelines, cleaner manufacturing, and regulatory momentum are driving interest in synthetic DNA. Explore how innovators are reducing bottlenecks and accelerating development.

39. FM Approval Standard 4882 9/21/2026

    A fire in a pharmaceutical cleanroom can be contained, but for sterile manufacturers, smoke can turn a localized event into a far wider decontamination, requalification, and production-recovery challenge.

40. Beyond The Starting Material: A Path To GMP Manufacturing Success 9/21/2026

    Explore how starting material decisions affect cell therapy development, tech transfer, and GMP readiness, as well as practical guidance for aligning material requirements with manufacturing processes.